KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Land & Improvements: 2011-2014

  • Ionis Pharmaceuticals' Land & Improvements changed negligibly% to $10.2 million in Q4 2014 from the same period last year, while for Dec 2014 it was $10.2 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $10.2 million for FY2014, which is negligibly% changed negligibly from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Land & Improvements of $10.2 million as of Q4 2014, which was down 0.00% from $10.2 million recorded in Q4 2013.
  • Over the past 5 years, Ionis Pharmaceuticals' Land & Improvements peaked at $10.2 million during Q4 2011, and registered a low of $10.2 million during Q4 2011.
  • Its 3-year average for Land & Improvements is $10.2 million, with a median of $10.2 million in 2014.